Sonoma Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Feb 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 5, 2025
SNOA$1.14+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
| Three Months Ended December 31, | Nine Months Ended December 31, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenues | $3,564 | $3,138 | $10,534 | $9,296 |
| Cost of revenues | 2,294 | 1,678 | 6,597 | 5,642 |
| Gross profit | 1,270 | 1,460 | 3,937 | 3,654 |
| Operating expenses: | ||||
| Research and development | 427 | 601 | 1,403 | 1,462 |
| Selling, general and administrative | 1,874 | 1,703 | 5,588 | 5,484 |
| Total operating expenses | 2,301 | 2,304 | 6,991 | 6,946 |
| Loss from operations | (1,031) | (844) | (3,054) | (3,292) |
| Other income (expense), net | 112 | (79) | 675 | (380) |
| Loss from operations before income taxes | (919) | (923) | (2,379) | (3,672) |
| Income tax (expense) benefit | (9) | 57 | (302) | (96) |
| Net loss | $(928) | $(866) | $(2,681) | $(3,768) |
| Net loss per share: basic and diluted | $(0.63) | $(1.59) | $(2.40) | $(10.74) |
| Weighted-average number of shares: basic and diluted | 1,464 | 546 | 1,117 | 351 |
| Other comprehensive loss: | ||||
| Net loss | $(928) | $(866) | $(2,681) | $(3,768) |
| Foreign currency translation adjustments | (357) | 297 | (1,831) | 595 |
| Comprehensive loss | $(1,285) | $(569) | $(4,512) | $(3,173) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.